The Ministry of Finance and two other departments issued an announcement regarding the transition of preferential policies on import value-added tax (VAT) after the implementation of the VAT Law. The announcement states that the preferential VAT policies on imports outlined in the "Notice of the Ministry of Finance, the General Administration of Customs, the State Taxation Administration, and the National Medical Products Administration on VAT Policies for Anti-Cancer Drugs" and the "Notice of the Ministry of Finance, the General Administration of Customs, the State Taxation Administration, and the National Medical Products Administration on VAT Policies for Rare Disease Drugs" will continue to be implemented from January 1, 2026 to December 31, 2027.
